Study of Trilaciclib and Lurbinectidin — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of Trilaciclib and Lurbinectidin — Stella

Home/Lung Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Lung Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, North Carolina

Key details

Phase

Safety & dosing

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

G1 Therapeutics, Inc.

Enrollment target

~30 participants

Started

October 2022

Primary completion

December 2026

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.